Medicines for the People Act
- Sponsor
- Rep. Tlaib, Rashida [D-MI-12]
- Committees
- Judiciary Committee (primary)
- Last action
- Mar 5, 2026
Bottom line
This bill creates a new federal institute to develop drugs, devices, and biological products, aiming to ensure public access and affordable pricing by federalizing intellectual property and manufacturing where feasible.
What it actually does
This bill establishes a National Institute for Biomedical Research and Development (NIBRD) within the Public Health Service Act. Its primary purpose is to engage in the full-cycle development of drugs, devices, and biological products, ensuring public health needs are prioritized and products are available at equitable and accessible prices. The Institute would own the intellectual property for products developed or funded by it, and would pursue public manufacturing where practicable, selling products at cost.
Proponents argue
Proponents argue that the bill addresses critical market failures in the pharmaceutical industry, such as high drug costs and a lack of innovation for neglected diseases, by creating a public entity focused solely on public health needs. They contend it will ensure long-term access to essential medicines and provide a significant return on public investment in research.
Opponents contend
Opponents typically argue that such a government-led initiative constitutes overreach into the private sector, potentially stifling private innovation by undermining intellectual property rights and creating inefficient government bureaucracy. They contend it could deter private investment in biomedical research and development, ultimately leading to fewer new treatments.
The bill is moderately complex due to its detailed provisions on intellectual property, governance, and operational mandates, but an informed reader can understand its core implications within a reasonable timeframe.
Section 2, new Section 464Z-11(a)
Establishment and Purpose of NIBRD
This provision establishes the National Institute for Biomedical Research and Development (NIBRD) with the core purpose of engaging in the full-cycle development of drugs, devices, and biological products. Its explicit goals are to promote long-term access to medicines, foster innovation, prioritize public health needs, and make these products available to the public at equitable and accessible prices.
Supporters argue
Supporters argue this provision is essential to correct market failures where private industry may neglect certain public health needs or price essential medicines out of reach. It ensures that public investment in research translates into public benefit.
Critics contend
Critics contend that this provision represents an unwarranted expansion of government into areas traditionally handled by the private sector, potentially leading to inefficiencies and stifling the very innovation it seeks to foster.
Tradeoffs
The provision balances the desire for affordable, accessible medicines with concerns about government efficiency and potential disruption to the existing private-sector innovation model.
Section 2, new Section 464Z-11(b)
Research and Development Program Activities
The Director of NIBRD is mandated to carry out a comprehensive research and development program. This includes direct R&D at federal labs, contracting with public or private entities, acquiring technologies, licensing patents, establishing new facilities, sharing scientific data, coordinating with other agencies, conducting clinical trials for FDA approval, performing health technology assessments, and other commercialization activities.
Section 2, new Section 464Z-11(c)
Acquisition of Rights to Inventions
The Director of NIBRD is required to monitor research funded by NIH and other public/private entities to identify inventions suitable for further development. Crucially, the Director is granted the right of first refusal to acquire the rights to any invention resulting from research conducted or supported by the National Institutes of Health, notwithstanding existing patent law (chapter 18 of title 35, United States Code).
Section 2, new Section 464Z-11(e)
Transparency Requirements
This section mandates high standards of transparency for NIBRD. It requires sharing preclinical, clinical, and cost data (deidentified) with researchers, manufacturers, and the public. Information on R&D priorities, data developed, summary findings, and all licensing agreements and contracts must be publicly available online. Additionally, entities funded by NIBRD must share scientific data promptly and submit peer-reviewed manuscripts to PubMed Central within one year of publication.
Section 2, new Section 464Z-11(f)
Federal Ownership and Management of Patents and Trade Secrets
This provision mandates that the Federal Government own the rights to any patents and trade secrets relating to drugs, devices, and biological products developed or funded by NIBRD, overriding existing patent law. The Director must manage these in the public interest, obtain patents, and license them to the Medicines Patent Pool. It also ensures public interest access (price and supply) through conditions on federal funding and non-exclusive licensing to public, nonprofit (free of cost), and for-profit entities (with public interest terms like cost-plus pricing and reciprocity). NIBRD is prohibited from claiming trade secrets or confidential commercial information.
Section 2, new Section 464Z-11(g)
Public and Private Manufacturing; Licensing; Royalties
For products patented by the Federal Government under this section and approved by the FDA, the Director must provide for public manufacturing "if practicable," with products sold "at cost." If public manufacturing is not practicable, the Director may license the patent to a private entity, prioritizing nonprofit organizations, based on health technology assessments. Royalties received from such licensing must be reinvested into NIBRD's R&D, and the Director may consider diversified, regional production when granting licenses.
Section 2, new Section 464Z-12
Governing Board Establishment and Membership
This section establishes a 15-member Governing Board for NIBRD, appointed by the Secretary, to set high-level policy and provide overall direction. Membership must include civil society representatives, patient advocates from independent organizations, and public health officials. Crucially, it imposes strict limitations: no more than 5 members from the for-profit sector, no lobbyists, and no current or former senior executive officers from 'covered entities' (companies with certain federal settlements or enforcement actions) for specified periods.
Section 2, new Section 464Z-14
Authorization of Appropriations
This section authorizes an appropriation of $90,000,000,000 (ninety billion dollars) for fiscal year 2027 to carry out the activities of the National Institute for Biomedical Research and Development. These funds are designated to remain available until expended, allowing for long-term investment and operational flexibility.
The definition of 'rights to an invention' is broad, encompassing all rights, title, and interests in an invention, including any sale, assignment, transfer of a patent (U.S. or foreign), and any exclusive license to a patent (U.S. or foreign).
Section 2, new Section 464Z-12(d)(4)
Why it matters:While definitions are often grouped, placing this broad definition under the Governing Board's section might make its full implications less immediately apparent when reading the IP provisions.
Case for: Supporters would argue that a comprehensive definition is necessary to ensure the federal government's ability to fully control and manage the intellectual property developed or acquired by NIBRD, consistent with its public interest mission.
Case against: Critics might argue that such a broad definition could be seen as overly aggressive by private entities, potentially deterring collaboration or the transfer of technologies to NIBRD, as it grants the government extensive control over any associated IP.
Estimated impact: Clarifies and expands the scope of federal control over intellectual property, ensuring that NIBRD's mandate for public ownership and access is legally robust.
The Governing Board is subject to the Federal Advisory Committee Act (FACA), but with an explicit exception: section 1013(a)(2) of title 5, United States Code, shall not apply. This specific section of FACA generally requires advisory committees to be open to the public and provide for public participation.
Section 2, new Section 464Z-12(i)
Why it matters:Such exceptions to transparency laws are often placed in less conspicuous locations, potentially to avoid drawing immediate attention to a reduction in public access or oversight for a new, powerful federal body.
Case for: Proponents might argue that this exception allows the Board to conduct sensitive policy discussions and strategic planning more efficiently and confidentially, without the administrative burden or potential for disruption associated with fully open meetings.
Case against: Critics would contend that exempting the Board from public participation requirements reduces transparency and accountability for a body making critical decisions about public health and significant federal spending, potentially allowing for less public scrutiny of its deliberations.
Estimated impact: Limits public access to the Governing Board's meetings and deliberations, potentially reducing public oversight of its decision-making processes.
This subsection amends Section 216 of title 18, United States Code (which deals with penalties for illegal gratuities and lobbying by former officials), to include violations related to Section 464z-12 of the Public Health Service Act. This means that certain prohibited communications or appearances by former NIBRD Governing Board members, made with intent to influence or gain information for financial markets, would be subject to criminal penalties.
Section 2(c)
Why it matters:Conforming amendments are typically placed at the end of a bill as technical adjustments to ensure consistency across federal law, making them easy to overlook by a casual reader focused on the primary policy changes.
Case for: Supporters would argue that this amendment is a necessary ethical safeguard, ensuring that former NIBRD Governing Board members are held to strict standards regarding post-service lobbying and financial market influence, preventing conflicts of interest and maintaining public trust.
Case against: Critics might contend that such provisions can be overly restrictive on former public servants, potentially discouraging qualified individuals from serving on the Board due to stringent post-employment limitations.
Estimated impact: Extends criminal penalties for certain lobbying activities to former members of the NIBRD Governing Board, strengthening ethics enforcement.